Research
Dr. Zhang is a Co-investigator of the NHGRI-funded U01 grant ‘Biorepositories for Genomic Medicine in Diverse Communities’, and is responsible for SNP and sequencing data analysis for projects of the National Human Genome Research Institute's ‘Electronic Medical Records and Genomics’ (eMERGE) II Network at MSSM. He is also a subcontract site - Principal Investigator of several National Institutes of Health funded projects including ' The Pathogenesis of HIV-Associated Nephropathy', ' Targeting Renal Inflammatory Pathways of SLE Nephritis in Mouse and Man' and ' DIaT as a transcriptional regulator of non-replicating Mycobacterium tuberculosis'.
Research Interests:
- Integrative analysis of candidate SNPs from genome-wide association analysis study of human complex diseases
- Algorithm and pipeline development of deep-sequencing analysis
- Genomics aberration study in cancer and hematological malignancies
Industry Relationships
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Zhang during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- VericiDx Inc
Royalty Payments:
- VericiDx
- VericiDx Inc
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.
Physicians and scientists on the faculty of the Icahn School of Medicine at Mount Sinai often interact with pharmaceutical, device and biotechnology companies to improve patient care, develop new therapies and achieve scientific breakthroughs. In order to promote an ethical and transparent environment for conducting research, providing clinical care and teaching, Mount Sinai requires that salaried faculty inform the School of their relationships with such companies.
Below are financial relationships with industry reported by Dr. Zhang during 2022 and/or 2023. Please note that this information may differ from information posted on corporate sites due to timing or classification differences.
Consulting:
- VericiDx Inc
Royalty Payments:
- VericiDx
- VericiDx Inc
Mount Sinai's faculty policies relating to faculty collaboration with industry are posted on our website. Patients may wish to ask their physician about the activities they perform for companies.